Autolus Therapeutics
AUTL
35 hedge funds and large institutions have $569M invested in Autolus Therapeutics in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 8 closing their positions.
2.74% more ownership
Funds ownership: 42.31% → 45.05% (+2.7%)
2% more capital invested
Capital invested by funds: $558M → $569M (+$11.3M)
8% less funds holding
Funds holding: 38 → 35 (-3)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$24.2M |
| 2 |
Millennium Management
New York
|
+$12.5M |
| 3 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$3.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$3.2M |
| 5 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$7.74M |
| 2 |
Jennison Associates
New York
|
-$3.51M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.6M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$928K |
| 5 |
AG
Artal Group
Luxembourg
|
-$711K |
AUTL Hedge Fund Activity: Q1 2019 in Review
35 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2019, worth a combined $569M — up 2% from $558M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of AUTL and 5 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 8 added.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $24.2M. The largest seller was Deerfield Management, exiting entirely with an estimated $7.74M sold.
- 35 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2019, down from 38 in Q4 2018.
- Funds reported $569M of Autolus Therapeutics stock for Q1 2019, up 2% quarter-over-quarter.
- 5 funds opened new Autolus Therapeutics positions in Q1 2019 and 8 closed out, a net change of -3 holders.
- The largest Autolus Therapeutics buyer in Q1 2019 was Cormorant Asset Management, an estimated $24.2M added.
- The largest Autolus Therapeutics seller in Q1 2019 was Deerfield Management, an estimated $7.74M sold.
Based on aggregated 13F filings for Q1 2019.